Federal Register of Legislation - Australian Government

Primary content

PB 11 of 2014 Arrangements as made
This instrument amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 - PB 116 of 2010 to add a new brand of a listed drug, and changes an existing responsible person code.
Administered by: Health
Registered 25 Feb 2014
Tabling HistoryDate
Tabled HR27-Feb-2014
Tabled Senate03-Mar-2014
Date of repeal 02 Mar 2014
Repealed by Division 1 of Part 5A of the Legislative Instruments Act 2003

 

PB 11 of 2014

National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 2)

 

National Health Act 1953

___________________________________________________________________________

 

 

I, KIM BESSELL, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the

National Health Act 1953.

Dated   20 February 2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

KIM BESSELL

Assistant Secretary

Pharmaceutical Access Branch

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

 

 


1       Name of Instrument

 

(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No.2).

 

(2)                This Instrument may also be cited as PB 11 of 2014.

 

2              Commencement

This Instrument commences on 1 March 2014.

3              Amendments to PB 116 of 2010

Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).

 

 


Schedule 1       Amendments

Section 3

[1]     Schedule 1, entry for Nevirapine in the form Tablet 200 mg

Insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

                       

Nevipin

GN

EMP

C3586 C3587 C3588 C3589

 

120

5

D

[2]     Schedule 2, entry for UA with Responsible Person Actavis Pty Ltd and Australian Business Number 17 003 854 626

          Omit.

[3]     Schedule 2, after entry for GK with Responsible Person GlaxoSmithKline Australia Pty Ltd and Australian Business Number 47 100 162 481

Insert:

 

GN

Actavis Pty Ltd

17 003 854 626